Chemipower OÜ

Active Registry code 16442800 OÜ Tallinn Registered 15 Feb 2022
Compare

Chemipower OÜ is a OÜ based in Tallinn, registry code 16442800, status: active. Main activity: Manufacture of basic pharmaceutical products. According to EMTA, turnover for Q3 2026 was €74 934 with 1 employees.

Turnover
74 934 €
↑ 232.7% vs Q2 2026
State taxes
1 092 €
↑ 110.4% vs Q2 2026
Labour taxes
739 €
Employees
1

Q3 2026 · data from the Tax and Customs Board (EMTA)

Position in the industry Manufacture of basic pharmaceutical products and pharmaceutical preparations · EMTAK 21

  • Turnover · Q3 2026 74 934 €
    industry median 234 187 € · companies in the industry: 12
  • Labour taxes per employee 739 €
    industry median 4 573 € · companies in the industry: 12
  • Revenue · 2025 48 003 €
    industry median 48 003 € · companies in the industry: 19
  • Net profit margin · 2025 -41.6 %
    industry median 9.8 % · companies in the industry: 15

Taxes and turnover

Q4 2023 – Q3 2026
Turnover, € Q3 2026: 74 934 € · +232.7% vs Q2 2026 · industry median 234 187 € · above 28% of the industry
0100 000200 000300 000400 000500 000Q4 2023 Company: 0 € Industry median: 102 827 €Q4·23Q1 2024 Company: 0 € Industry median: 160 070 €Q2 2024 Company: 10 166 € Industry median: 216 097 €Q2·24Q3 2024 Company: 2 380 € Industry median: 261 493 €Q4 2024 Company: 6 090 € Industry median: 198 576 €Q4·24Q1 2025 Company: 5 745 € Industry median: 231 372 €Q2 2025 Company: 8 189 € Industry median: 292 853 €Q2·25Q3 2025 Company: 11 118 € Industry median: 423 731 €Q4 2025 Company: 20 338 € Industry median: 410 601 €Q4·25Q1 2026 Company: 15 580 € Industry median: 375 496 €Q2 2026 Company: 22 526 € Industry median: 198 786 €Q2·26Q3 2026 Company: 74 934 € Industry median: 234 187 €Q3·260100 000200 000300 000400 000500 000Q4 2024 Company: 6 090 € Industry median: 198 576 €Q1 2025 Company: 5 745 € Industry median: 231 372 €Q1·25Q2 2025 Company: 8 189 € Industry median: 292 853 €Q3 2025 Company: 11 118 € Industry median: 423 731 €Q3·25Q4 2025 Company: 20 338 € Industry median: 410 601 €Q1 2026 Company: 15 580 € Industry median: 375 496 €Q1·26Q2 2026 Company: 22 526 € Industry median: 198 786 €Q3 2026 Company: 74 934 € Industry median: 234 187 €Q3·26
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Labour taxes per employee, € Q3 2026: 739 € · industry median 4 573 € · above 8% of the industry
01 0002 0003 0004 0005 000Q4 2023 Company: — Industry median: 3 627 €Q4·23Q1 2024 Company: — Industry median: 3 668 €Q2 2024 Company: — Industry median: 3 706 €Q2·24Q3 2024 Company: — Industry median: 3 971 €Q4 2024 Company: — Industry median: 3 921 €Q4·24Q1 2025 Company: — Industry median: 4 259 €Q2 2025 Company: — Industry median: 3 971 €Q2·25Q3 2025 Company: — Industry median: 4 236 €Q4 2025 Company: — Industry median: 4 504 €Q4·25Q1 2026 Company: — Industry median: 4 205 €Q2 2026 Company: — Industry median: 4 757 €Q2·26Q3 2026 Company: 739 € Industry median: 4 573 €Q3·2601 0002 0003 0004 0005 000Q4 2024 Company: — Industry median: 3 921 €Q1 2025 Company: — Industry median: 4 259 €Q1·25Q2 2025 Company: — Industry median: 3 971 €Q3 2025 Company: — Industry median: 4 236 €Q3·25Q4 2025 Company: — Industry median: 4 504 €Q1 2026 Company: — Industry median: 4 205 €Q1·26Q2 2026 Company: — Industry median: 4 757 €Q3 2026 Company: 739 € Industry median: 4 573 €Q3·26
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Employees Q3 2026: 1
0.00.20.40.60.81.0Q4 2023 Company: —Q4·23Q1 2024 Company: —Q2 2024 Company: —Q2·24Q3 2024 Company: —Q4 2024 Company: —Q4·24Q1 2025 Company: —Q2 2025 Company: —Q2·25Q3 2025 Company: —Q4 2025 Company: —Q4·25Q1 2026 Company: —Q2 2026 Company: —Q2·26Q3 2026 Company: 1Q3·260.00.20.40.60.81.0Q4 2024 Company: —Q1 2025 Company: —Q1·25Q2 2025 Company: —Q3 2025 Company: —Q3·25Q4 2025 Company: —Q1 2026 Company: —Q1·26Q2 2026 Company: —Q3 2026 Company: 1Q3·26
State taxes, € Q3 2026: 1 092 € · +110.4% vs Q2 2026
02505007501 0001 250Q4 2023 Company: —Q4·23Q1 2024 Company: —Q2 2024 Company: —Q2·24Q3 2024 Company: —Q4 2024 Company: —Q4·24Q1 2025 Company: 812 €Q2 2025 Company: 710 €Q2·25Q3 2025 Company: 492 €Q4 2025 Company: 81 €Q4·25Q1 2026 Company: 757 €Q2 2026 Company: 519 €Q2·26Q3 2026 Company: 1 092 €Q3·2602505007501 0001 250Q4 2024 Company: —Q1 2025 Company: 812 €Q1·25Q2 2025 Company: 710 €Q3 2025 Company: 492 €Q3·25Q4 2025 Company: 81 €Q1 2026 Company: 757 €Q1·26Q2 2026 Company: 519 €Q3 2026 Company: 1 092 €Q3·26
Figures by quarter
Quarter Turnover, € State taxes, € Labour taxes, € Employees
Q3 2026 74 934 1 092 739 1
Q2 2026 22 526 519 — —
Q1 2026 15 580 757 — —
Q4 2025 20 338 81 — —
Q3 2025 11 118 492 — —
Q2 2025 8 189 710 — —
Q1 2025 5 745 812 — —
Q4 2024 6 090 — — —
Q3 2024 2 380 — — —
Q2 2024 10 166 — — —
Q1 2024 — — — —
Q4 2023 — — — —
Q3 2023 — — — —
Labour taxes per employee per month
246 €
Turnover per employee in the quarter
74 934 €

Q3 2026 · calculated from EMTA data

Financials by year

2022 – 2025
Revenue, € 2025: 48 003 € · +242.9% vs 2024 · industry median 48 003 € · above 50% of the industry
010 00020 00030 00040 00050 0002022 Company: — Industry median: 4 897 €20222023 Company: — Industry median: 3 851 €20232024 Company: 14 000 € Industry median: 25 284 €20242025 Company: 48 003 € Industry median: 48 003 €2025010 00020 00030 00040 00050 0002022 Company: — Industry median: 4 897 €2023 Company: — Industry median: 3 851 €20232024 Company: 14 000 € Industry median: 25 284 €2025 Company: 48 003 € Industry median: 48 003 €2025
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit, € 2025: -19 960 € · −494.7% vs 2024 · industry median 676 € · above 19% of the industry
-20 000-10 000010 0002022 Company: -5 314 € Industry median: 0 €20222023 Company: -1 586 € Industry median: 0 €20232024 Company: 5 057 € Industry median: 0 €20242025 Company: -19 960 € Industry median: 676 €2025-20 000-10 000010 0002022 Company: -5 314 € Industry median: 0 €2023 Company: -1 586 € Industry median: 0 €20232024 Company: 5 057 € Industry median: 0 €2025 Company: -19 960 € Industry median: 676 €2025
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Net profit margin, % 2025: -41.6 % · −77.7 pp vs the year before · industry median 9.8 % · above 20% of the industry
-60-40-20020402022 Company: — Industry median: -1.9 %20222023 Company: — Industry median: 4.4 %20232024 Company: 36.1 % Industry median: 1.2 %20242025 Company: -41.6 % Industry median: 9.8 %2025-60-40-20020402022 Company: — Industry median: -1.9 %2023 Company: — Industry median: 4.4 %20232024 Company: 36.1 % Industry median: 1.2 %2025 Company: -41.6 % Industry median: 9.8 %2025
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Assets, € 2025: 91 582 € · +2.9% vs 2024
020 00040 00060 00080 000100 0002022 Company: 7 419 €20222023 Company: 29 596 €20232024 Company: 88 981 €20242025 Company: 91 582 €2025020 00040 00060 00080 000100 0002022 Company: 7 419 €2023 Company: 29 596 €20232024 Company: 88 981 €2025 Company: 91 582 €2025
Equity, € 2025: -19 303 € · −3 038.1% vs 2024
-20 000-15 000-10 000-5 00005 0002022 Company: -2 814 €20222023 Company: -4 400 €20232024 Company: 657 €20242025 Company: -19 303 €2025-20 000-15 000-10 000-5 00005 0002022 Company: -2 814 €2023 Company: -4 400 €20232024 Company: 657 €2025 Company: -19 303 €2025
Employees 2025: 0 · industry median 28 · above 2% of the industry
0102030402022 Company: 0 Industry median: —20222023 Company: 0 Industry median: 2520232024 Company: 0 Industry median: 3220242025 Company: 0 Industry median: 2820250102030402022 Company: 0 Industry median: —2023 Company: 0 Industry median: 2520232024 Company: 0 Industry median: 322025 Company: 0 Industry median: 282025
  • Company
  • Industry median

Industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations (the EMTAK division of the main activity). Median: half of the industry is above, half below.

Financials by year
Year Revenue, € Net profit, € Labour costs, € Assets, € Equity, € Employees
2025 48 003 -19 960 0 91 582 -19 303 0
2024 14 000 5 057 0 88 981 657 0
2023 — -1 586 0 29 596 -4 400 0
2022 — -5 314 0 7 419 -2 814 0

Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.

Financial ratios for 2025

Net profit margin
-41.6 %
Net profit / revenue
Return on assets (ROA)
-21.8 %
Net profit / assets
Equity ratio
-21.1 %
Equity / assets
Debt ratio
121.1 %
Liabilities / assets
Current ratio
3.06
Current assets / current liabilities

Annual reports

PDFs from e-Äriregister
Annual reports
Year Period Filed Report Documents
2025 1 Jan 2025 – 31 Dec 2025 2 Sep 2026 Company’s own e-Äriregister
2024 1 Jan 2024 – 31 Dec 2024 4 Jun 2025 Company’s own e-Äriregister
2023 1 Jan 2023 – 31 Dec 2023 26 Jul 2024 Company’s own e-Äriregister
2022 15 Feb 2022 – 31 Dec 2022 4 Jul 2023 Company’s own e-Äriregister

Board

Right of representation

Any member of the management board may represent the private limited company in all transactions.

Owners

Beneficial owners

  • Aare-Laidar Laos
    Member of a senior management body (management or supervisory board) · since 15 Feb 2022
  • Anne Laos
    Indirect ownership · since 15 Feb 2022
  • Ants Laos
    Indirect ownership · since 15 Feb 2022
  • Elizabeth Põder
    Member of a senior management body (management or supervisory board) · since 15 Feb 2022
  • Jaanus Põder
    Member of a senior management body (management or supervisory board) · since 15 Feb 2022
  • Liivar Laos
    Indirect ownership · since 15 Feb 2022

Founders and other persons

shared board members, owners or beneficial owners

Activities (EMTAK)

  • 21101Manufacture of basic pharmaceutical products Main

Rulings 4

All rulings (PDF)
Rulings
Number, date Title Deadline State Document
Ä 50196615 / M1
19 Jul 2024
 Warning of deletion from the register: annual report not filed 22 Oct 2024 Deficiencies eliminated
27 Jul 2024
 PDF
Ä 50196615 / 3
1 Sep 2023
 Amendment entry In force
1 Sep 2023
 PDF
Ä 50196615 / 2
31 Jan 2023
 Amendment under Commercial Code § 525 (2) In force
31 Jan 2023
 PDF
Ä 50196615
15 Feb 2022
 First entry In force
15 Feb 2022
 PDF

Sources: e-Äriregister and EMTA. Data updated 31 Oct 2026. Open at the source ↗ · Report an error in the data